Next Science Limited (NXS) TRADING HALT SUSPENDED

20mins delayed

Movement

1 Year Return

System message

16 Sept 2019: Updates have been made to Broker Consensus and Highest Dividends.

Get these alerts in your email: Signup Free Here

Next Science Limited Chart

Share price
Last
Change
Volume
Turnover
Market Cap $317.84 million
Today's Movement
Prev. Close
Open
Day Range -
VWAP
Historical Stats
52w Range -
4w Avg Volume
4w Avg Turnover
(delayed)

NXS Statistics

19 September

448 / 2,298

ASX Size Rank

1yr Return

vs Sector (1yr)

+109.12%

vs ASX 200 (1yr)

+114.44%

$317.84 million

Market Cap

Share Issue

105.6 million

All Ords (%)

N/A

Short Sold

0.1%

Current Fundamentals

19 September

N/A

PE Ratio

EPS ($)

-0.062

Earnings Yield

-2.05%

NTA ($)

0.18

N/A

Dividend Yield

DPS ($)

-

Gross Div. Yield

-

Gross DPS ($)

-

Company Overview

Next Science Limited (NXS) is a medical technology with a research and development centre in Florida, USA. NXS has four FDA cleared products currently available in the US market to treat and manage surgical site infections and chronic wounds. NXS owns 100% of the patent protected intellectual property relating to its Xbio technology. NXS products are as below:

Next Science Limited Logo

Corporate Details

Head Office: Chatswood
Managing Director: Judith Mitchell
GICS Sub-Industry: Health Care Supplies
Date Listed: 18 Apr 2019
Registry: -
Similar Companies: RMD / COH / FPH / ANN / NAN

Upcoming Calendar

Dividend History

Ex-Date Amount Franking Type Payable
No dividends paid in the last 5 years

See Upcoming Dividends for all ASX companies.

Announcements

Date Heading Pages File Size Time

Broker Consensus

The buy, hold and sell recommendations from Australian stockbroking firms are combined to form a "broker consensus". See the Consensus Data posts for more information.

NXS is not covered by a major broker.

Directors & Management

About the Data


Name Title Since Bio
Mr Mark Raymond Compton Non-Executive Director Oct 2018
Mr George Savvides Non-Executive Chairman, Non-Executive Director Jul 2018
Mr Bruce Alan Hancox Non-Executive Director Oct 2017
Mr Dan Spira Non-Executive Director Oct 2017
Mrs Aileen Stockburger Non-Executive Director Oct 2018
Ms Judith Mitchell Managing Director Oct 2017

Director Transactions

About the Data

NXS directors must report any change in shareholding to the ASX within 5 business days.

See Director Transactions for all ASX companies.

There are no director transactions for code NXS in our database.

Shareholder Distribution

Shareholder Distribution data is unavailable.

Top 20 Shareholders

About the Data

Name Shares Capital
Auckland Trust Company Ltd 46,507,500 25.96%
Walker Group Holdings Pty Ltd 29,003,000 16.19%
Matthew Myntti 20,657,000 11.53%
Christopher Samuel 7,299,500 4.07%
James Mozley 6,435,000 3.59%
Judith Mitchell 4,732,000 2.64%
HSBC Custody Nominees (Australia) Limited 4,579,167 2.56%
National Nominees Limited 4,450,000 2.48%
UBS Nominees Pty Ltd 2,000,000 1.12%
Charles Robert Dirck Wittenoom 1,950,000 1.09%
Belgravia Strategic Equities Pty Ltd 1,875,000 1.05%
J P Morgan Nominees Australia Pty Limited 1,800,000 1.00%
Portfolio Services Pty Ltd 1,781,000 0.99%
Scone Investments Pty Ltd 1,781,000 0.99%
BNP Paribas Noms Pty Ltd 1,600,000 0.89%
Citicorp Nominees Pty Limited 1,544,000 0.86%
Merrill Lynch (Australia) Nominees Pty Limited 1,500,000 0.84%
Byron Darroch 1,170,000 0.65%
Michael Anderson 1,124,500 0.63%
Aust Executor Trustees Ltd 1,000,000 0.56%
All other shareholders 20.31 %


The Top 20 Shareholders of NXS hold 79.69% of shares on issue.

NXS Share Price History

Date Close Change % Change Open High Low Volume Turnover

NXS Historical Data

Download up to 20 years of share price history.


Year Closing Price (30 June) Last Trade

Offical data as published by ASX. See more Data Downloads.

Company Details

Principal Activity: Commercialising and developing its Xbio technology, which is a non-toxic technology with proven efficacy in eradicating both biofilm based and free-floating bacteria, in a range of products for the treatment of biofilm based infections.

Incorporated: --

Suite 1902, Level 19, Tower A The Zenith Building, 821 Pacific Hwy
Chatswood NSW 2067


All data on this page is supplied by the ASX, Morningstar and Market Index. Read the disclaimer.